ArticleTobacco induced diseases2022
Burden of current and past smoking across 28 European countries in 2017: A cross-sectional analysis.
Article in Tobacco induced diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Simultaneous versus Sequential Cessation of Tobacco and Cannabis: Preferences of Young Adults Who Co-Use in France.Drug and alcohol review · 2026Article
- The landscape of lung cancer screening globally: a comparison of established programs and estimates of eligibility to participate.The Lancet regional health. Western Pacific · 2026Review
- Past trends, future forecasts and socio-demographic patterns of cigarette smoking in Belgium, 1997 to 2040.Population health metrics · 2026Article
- European Code Against Cancer, 5th edition - tobacco and nicotine containing products, second-hand smoke, alcohol and cancer.Molecular oncology · 2026Review
- Social determinants of support for tobacco control policies to end the use of commercial cigarettes: findings from the 2022 International Tobacco Control Four Country Smoking and Vaping Survey.Tobacco control · 2025Article
- Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based realworld cohort study from Denmark and France.Haematologica · 2025Article
- Nicotine Misuse and Treatment of Schizophrenia Exacerbations in Men: An Observational Study in Poland.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Age-period-cohort analysis of cardiovascular disease trends in middle-aged and older adults: cross-country comparison across HRS, ELSA, SHARE, and CHARLS.Journal of global health · 2025Article
- Socioeconomic Variation in Tobacco Smoking Among the Adult Population in Ireland.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Article
- Prevalence and characteristics of tobacco use among adults in Kazakhstan: A cross-sectional National Survey.Global epidemiology · 2025Article
- Article
- Global, regional, and national burden of laryngeal cancer attributable to smoking, 1990-2021, and projections to 2036: a systematic analysis of the Global Burden of Disease study 2021.Frontiers in public health · 2025Article
- Mapping indicators of tobacco and related product use: Unveiling challenges and variations in the Eurobarometer surveys over three decades.Tobacco induced diseases · 2025Article
- Impact of tobacco control policies on socioeconomic inequalities in smoking prevalence and quit ratios: an ecological study in the European Union (2009-2020).BMJ public health · 2025Article
- Next generation brain health: transforming global research and public health to promote prevention of dementia and reduce its risk in young adult populations.The lancet. Healthy longevity · 2024Review
- First experience with nicotine products and transition to regular tobacco use: a secondary data analysis in 28 European countries.BMJ open · 2024Article
- Analyzing arguments on tobacco tax increases. Focus on French parliamentary questions and responses, 2000-2020.Tobacco induced diseases · 2024Article
- Sociodemographic inequalities in cigarette, smokeless tobacco, waterpipe tobacco, and electronic cigarette use among adolescents aged 12-16 years in 114 countries: A cross-sectional analysis.Tobacco induced diseases · 2024Article
- Electronic cigarette use and consumption patterns in medical university students.Frontiers in public health · 2024Article
- The smoking and vaping model, A user-friendly model for examining the country-specific impact of nicotine VAPING product use: application to Germany.BMC public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMost studies use the prevalence of current smoking as an indicator to quantify the burden of smoking. However, length and intensity of smoking, as well as time since cessation for former smokers are also known to impact smoking-related health risks. The aim of this study was to quantify and compare the burden of smoking across the European Union (EU) using a range of smoking burden indicators.
methodsWe conducted a cross-sectional analysis using data from the March 2017 Eurobarometer 87.1 (n=27901, people aged ≥15 years) in 28 European Union Member States (EU MS) and the Tobacco Control Scale. We defined five indicators of smoking burden including the prevalence of current and ever smoking, length of smoking, pack-years, and discounted pack-years, and ranked EU MS by each indicator. Two-level linear and logistic regressions were performed to assess the association between these indicators and sociodemographic and tobacco policy factors.
resultsWide variations across the EU countries were observed in all smoking burden indicators. While some MS ranked consistently high (e.g. Greece, France) or consistently low (e.g. Ireland, United Kingdom) in all indicators, we found substantial discrepancies in ranking depending on the indicator used for MS such as Malta, Denmark, Finland and the Netherlands. All indicators of smoking burden were lower among women and respondents without financial difficulties; however, the magnitude of those inequalities varied two-fold among the different indicators.
conclusionsUsing a range of smoking burden indicators can be more informative than relying on prevalence alone. Our analysis highlights the limitations of relying solely on prevalence of current smoking to estimate the burden of smoking and the potential value of more nuanced indicators. We recommend that multiple and more nuanced indicators that consider former smokers, intensity and duration of smoking should be utilized to monitor tobacco use and evaluate tobacco control policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.